Hydrogenology
Source-linked study record

Molecular Hydrogen Therapy in Sjögren’s Syndrome With Pulmonary Arterial Hypertension and Right-sided Heart Failure: A Case Report of Improved Immune Markers Including Treg, B Cells and Plasma Cell

Lin YT, Lu JW, Wu CH, Ho YJ, Lui SW, Hsieh TY, Liu FC. · In vivo (Athens, Greece). 2024;38(6):3117-3124.

HumanOther formsPublished 2024Source checked
Study record, not medical adviceThis record reports what the source states. It is not medical advice and does not establish that molecular hydrogen is effective, safe or appropriate for any person.
Quick summary

Study at a glance

Evidence type

Human

Population or model

One woman with Sjögren’s syndrome, pulmonary arterial hypertension and right-sided heart failure.

Intervention and dose

One oral H₂-generating capsule per day, initiated in May 2023 as adjunctive therapy. · Each capsule contained 170 mg hydrogen-rich coral calcium and was described as providing approximately 1.7×10²¹ hydrogen molecules. The article gives a theoretical equivalence to 24 cups of water at 1,200 ppb or 0.6 mM per 200 mL; those are not directly administered water doses.

Duration

Daily from May 2023 through the reported follow-up.

Reported result

Article-reported result excerpt (24 words maximum): “Adjuvant therapy with hydrogen capsules resulted in increased CD127 + Treg, decreased anti-Ro antibody, decreased B cell subsets ([Figure 3] and [Figure 4]), and…” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.

Main limitation

Human evidence; design, sample size and comparator limit interpretation. Funding or grant information is reported in the full article. The article declares no conflicts of interest.

Evidence and classification

What kind of evidence is this?

Evidence type

Human

Reported design

Case report

Research topic

Cardiovascular and circulatory health

Administration form

Other forms

Information not yet classified

Some editorial classification fields are still pending. The source-reported outcomes and result are shown below; Hydrogenology does not infer a positive or negative signal from prose automatically.

Reported in the source

Methods

Population or model

One woman with Sjögren’s syndrome, pulmonary arterial hypertension and right-sided heart failure.

Sample

Single-patient case report.

Duration

Daily from May 2023 through the reported follow-up.

Intervention

One oral H₂-generating capsule per day, initiated in May 2023 as adjunctive therapy.

Hydrogen form

an oral H₂-generating preparation — H₂ only unless the full text explicitly reports oxygen co-delivery.

Dose or H₂ specification

Each capsule contained 170 mg hydrogen-rich coral calcium and was described as providing approximately 1.7×10²¹ hydrogen molecules. The article gives a theoretical equivalence to 24 cups of water at 1,200 ppb or 0.6 mM per 200 mL; those are not directly administered water doses.

Comparator

No concurrent control; before-and-after observations in one patient receiving other therapies.

Reported, not endorsed

Outcomes and reported result

Outcomes measured

survival or mortality, clinical symptoms or functional scores, inflammation and cytokines, oxidative-stress and antioxidant markers, apoptosis or cell injury, histology or tissue damage

Reported result

Article-reported result excerpt (24 words maximum): “Adjuvant therapy with hydrogen capsules resulted in increased CD127 + Treg, decreased anti-Ro antibody, decreased B cell subsets ([Figure 3] and [Figure 4]), and…” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.

Extraction completeness

The complete machine-readable article was checked for source identity, methods, intervention quantities, results, tables, funding and conflict declarations. This public record is based on the full article.

A reported association, difference or mechanism is not automatically a clinical benefit.

Interpretation limits

Limitations and applicability

Main methodological cautions

Human evidence; design, sample size and comparator limit interpretation. Funding or grant information is reported in the full article. The article declares no conflicts of interest.

Applies directly to

Applies only to the population and protocol reported in this cardiovascular and circulatory health article.

No single-study GRADE certainty rating is assigned. Read how records and evidence assessments are prepared.

Sources and status

Sources and record status

Identifiers

PMID: 39477378 · DOI: 10.21873/invivo.13797

Publisher access

A free full article is available through PubMed Central.

Extraction basis

Official PubMed/PMC full article; record re-audited and corrected 25 August 2026.

Last reviewed

25 August 2026

Help the next reader

Help people check the facts before they buy.

Hydrogenology keeps 665 source-checked records accessible without advertising or product promotion.

Support independent access
Help us correct the recordReport a discrepancy

Send the exact difference between this page and the linked source. The study reference is attached automatically.